Articles On Opthea (ASX:OPT)

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. The stock market has...

Recent cap raising suggests biotechs may finally be making a comeback Mesblast annnounced a US$45m cap raise last week Today, Paradigm, Opthea, and Proteomics also announced fund raises Over the past year, the biotech sector has been caug...

The S&P/ASX 200 Materials Index (ASX: XMJ) is lifting 1.65% today, but three ASX mining shares are outperforming the index. The Belararox Ltd (ASX: BRX), Aurelia Metals Ltd (ASX: AMI) and Sarytogan Graphite Ltd (ASX: SGA) are all risi...

Opthea (ASX:OPT) has announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics to progress the development of OPT-302 for wet age-related macular degeneration....

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX Powerplays. Several ASX health stocks have...

ASX 200 and small caps rise circa 1% Regional markets jump on strong leads, US inflation data Ragusa Metals: up 60% Local markets took off at the open, feeling a little of the excitement which took hold of Wall Street overnight. The bench...

Opthea (OPT) enters into a trading halt ahead of a capital raise There is currently no details on how much the company is aiming to raise however did mention of an upcoming funding agreement Under the halt, company shares will be paused un...

It’s a big day for ASX-listed Opthea, an eye therapies developer with a near $500 million market capitalisation. 

The Carlyle Group and its newly acquired life sciences arm Abingworth are chasing a four-bagger at Australian eye therapies developer Opthea.

What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

ShareCafeQueuing at the ATM: ASX small caps discover a handy source of funding ASX-listed small cap companies are flocking to the ATM for a ready source of cash, at a time and amount of their choosing. In this case, ATM does not refer to th...

May. Let’s start with US markets. Because May in the US started with the Dow making its biggest gain since 2020, followed within 24 hours by its biggest loss in 2022, perfectly summing up what kind of month May was to become. The US Fed rai...

Retinal biopharmaceutical company Opthea (OPT) presented its clinical data at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting The presentation was titled “Efficacy and Safety of OPT-302 in combination wi...

Opthea presents data at a renowned medical conference Osprey slashes workforce and is considering fresh cap raise Opthea presents data at conference Retinal diseases company Opthea Limited (ASX:OPT) rose by 1% today amongst a sea of reds....

  US stocks plunge in a broad based selloff Block Inc down 10% on NYSE as earnings disappoint ASX to open 1.5% lower this morning ASX to tumble as Wall Street dives The ASX 200 is set to open much lower this morning, following a broad sel...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Opthea (ASX:OPT) has announced the appointment of Quinton Oswald and Dr Susan Orr to its board of directors.

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Opthea (ASX:OPT) has announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference.

Clinical stage biopharmaceutical company  Opthea (ASX:OPT) has received a $6.6 million research and development tax credit from the Australian Taxation Office.

The ASX 200 Health Index (XHJ) is falling by 1.5% at the time of writing, compared to the broader index which is down by 0.30%. Two ASX-listed companies will be presenting at the annual H.C. Wainwright BIOCONNECT Virtual Conference, to be h...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

In October, the Chinese government released its intellectual proprietary (IP) patents strategy paper, listing its main goals for the next five years. Part of that plan is to double the foreign “high value” patents from the current 40,000 to...

27 Oct 2021 - Opthea (ASX:OPT) has been granted a Chinese patent covering its lead compound OPT-302.

Wall Street touches record highs All three US stock benchmark indexes rose again overnight, as the Dow and the S&P500 reached new all-time highs in intraday trade. The Dow closed 0.04% higher, while the S&P 500 was up by 0.18%, and...

Opthea (OPT) opens patient enrolment for its Phase 3 clinical program for the treatment of wet age-related macular degeneration in the Asia-Pacific region OPT says the clinical trial sites build upon the progress of other international reg...

As the world emerges from the pandemic, markets are now contending with an energy crisis, a global shipping glut and the prospect of central banks starting to raise interest rates. But so far this week, investors are shrugging it all off as...

The ASX 200 Health Index (XHJ) is up by 1.2% at the time of writing, compared to the broader index which is higher by 1%. Truscreen Group (ASX:TRU) was the best health stock performer, up by 38% after reporting key milestones including the...

Wall Street continues recent bull run All three US indices rallied again overnight, with oil prices and Bitcoin also surging to recent highs. The Dow Jones lifted 0.56%, the S&P 500 by 0.74%, and tech heavy Nasdaq by 0.71%. Solid earnin...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed Wall Street’s lead and is tumbling lower. At the time of writing, the benchmark index is down 0.75% to 7,224.5 points. Four ASX shares that are falling more than most to...

The ASX 200 health stocks index (XHJ) is falling by 0.55% at the time of writing, compared to the broader ASX 200 index which fell by 0.50%. Fibrotic and inflammatory diseases-focused biotech, Pharmaxis (ASX:PXS), has just announced further...

Opthea (ASX:OPT) has announced that enrollment in its pivotal Phase 3 clinical program of OPT-302 for the treatment of wet age-related macular degeneration is now open in Europe.

Tech stocks drag Wall Street lower A selloff in technology stocks dragged Wall Street sharply lower overnight, amid concerns of higher inflation. All three US stock market benchmarks fell – with the Dow Jones dropping by 0.94%, the S&P...

Looking for some small cap shares to add to your watchlist? Then have a look at the ones listed below. Here’s why they could be worth getting better acquainted with: Bigtincan Holdings Ltd (ASX: BTH) The first small cap to watch is Bigti...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX200 health stocks index (XHJ) fell by 0.14% this morning, compared to the broader index which rose by 0.35%. Medical imaging specialist, EMVision (ASX:EMV), has rocketed by 16% after announcing that 1st Gen portable brain scanner has...

Clinical stage biopharmaceutical company Opthea (ASX:OPT) has announced that recruitment is open to patients in Canada for the Phase 3 pivotal clinical program of OPT-302 for the treatment of wet age-related macular degeneration....

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week Healthcare fi...